1.Integration of Intellectual Technology and Public Health:Creating Smart Healthy Cities
Xi WANG ; Danlei WANG ; Chongyi WANG ; Ayan MAO ; Xiaoling YAN ; Minjiang GUO ; Xiaohu MENG ; Wei WANG ; Wuqi QIU
Journal of Medical Informatics 2024;45(7):1-6
Purpose/Significance Based on the concepts of healthy cities and smart cities,the paper introduces a new concept-smart healthy cities.It explores the definition,scope,function,challenges,and strategic responses associated with the concept.Meth-od/Process Through literature review and case study analysis,the theoretical foundations,characteristics,objectives,and implementa-tion strategies of healthy cities and smart cities are compared,revealing differences and points of convergence,proposing the origins,def-initions,and delineations of smart healthy cities,and exploring the relationships among healthy cities,smart cities,and smart healthy cit-ies.Result/Conclusion Smart healthy cities enhance urban health governance and the well-being of residents through technological in-novation.Effective integration of advanced technologies with urban governance policies is essential,alongside the implementation of di-verse strategies to drive progress.Future urban development should focus more on the theoretical and practical collaborative development within the smart healthy cities framework.
2.The Development Status and Trend of Intelligent Technologies Applied in the Medical Field in China
Zhongyuan ZHANG ; Lin MA ; Xiaohu MENG ; Wei WANG ; Zhiying LI ; Minjiang GUO ; Wuqi QIU
Journal of Medical Informatics 2024;45(7):7-13
Purpose/Significance To expound the development of the application of new generation intelligent technologies in the medi-cal field in China,and to provide ideas for the future development of intelligent medical technologies in China.Method/Process Literature related to the application of medical intelligence technology from 2000 to 2023 is searched and screened on CNKI,and the knowledge graph is drawn by descriptive statistical analysis and CiteSpace software for visualization analysis.Result/Conclusion The number of papers pub-lished in the application research field of domestic medical intelligence technology shows a trend of steady growth and then leveling off.The hot keywords mainly include smart medical care,health care,health management,etc.,forming 8 main cluster sets.Future research should strengthen cooperation and exchanges between researchers and organizations,and pay more attention to the challenges posed by the applica-tion of technology in terms of security and privacy,technology supervision,talent team construction and technological energy consumption.
3.Policy Analysis and Interpretation for Smart Healthy Cities
Xi WANG ; Chongyi WANG ; Danlei WANG ; Ayan MAO ; Xiaoling YAN ; Minjiang GUO ; Lin MA ; Xiaohu MENG ; Wei WANG ; Wuqi QIU
Journal of Medical Informatics 2024;45(8):35-40,63
Purpose/Significance To explore the technical key points and implementation paths of relevant policies,and provide ref-erence for the planning and construction of future smart healthy cities.Method/Process It reviews and analyzes domestic and internation-al policy progress in the field of smart healthy cities,deeply analyzes policy documents,reveals the evolution trajectory,core elements,and driving effects on urban health development.Result/Conclusion Establishing a framework for health informatization,resource net-working,intelligent services,and integrated supervision can effectively address urban health challenges,provide efficient health services,and improve residents'quality of life and hygiene level.Policies such as optimizing the allocation of medical resources,promoting coordi-nation and cooperation among medical institutions,and expanding the health industry will jointly promote the sustained progress of urban health ecosystems.
4.Results of EGFR Mutations Detected in Pleural Effusion and Its Clinical Significance in 132 Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study in A Single Center.
Tao LU ; Qiang LI ; Lan LI ; Kaizhen YANG ; Danfei ZHOU ; Jie GAO ; Minjiang CHEN ; Yan XU ; Wei ZHONG ; Mengzhao WANG ; Zhiyong LIANG ; Jing ZHAO
Chinese Journal of Lung Cancer 2020;23(12):1059-1065
BACKGROUND:
The lack of pathological quality control standard in detecting epidermal growth factor receptor (EGFR) gene mutation in malignant pleural effusion leads to confusion in the interpretation of detection results and the clinical use of EGFR-tyrosine kinase inhibitor (TKI). Therefore, it is very important to propose quality control standards and guide the detection of EGFR mutation in pleural effusion. The aim of this study is to retrospectively analyze the results of EGFR gene mutation in pleural effusion sediment section according to strict pathological quality control standards, and the therapeutic effect of EGFR-TKIs guided by this detection results.
METHODS:
From January 2012 to June 2018, the clinical data of patients with pleural effusion collected from Department of Pathology of Peking Union Medical College Hospital were analyzed retrospectively. Among them, 132 patients with relatively complete clinical data and with EGFR gene mutation detection of paraffin-embedded pleural effusion sediment section according to the established quality control standard were included. According to the results of EGFR gene mutation, it was divided into positive group and negative group, and the efficacy of EGFR-TKIs in different groups was compared.
RESULTS:
After the centrifugation of pleural effusion, the sediment was embedded in paraffin, sectioned, and observed under the microscope after HE staining. If the number of tumor cells ≥100, it met the pathological quality control standard, and it could be used for subsequent EGFR gene mutation detection. EGFR gene mutations were detected in 72 (54.5%) of 132 patients. EGFR-TKIs were used in 69 of 72 mutation positive patients. Of 60 EGFR mutation negative patients, only 15 used EGFR-TKIs. In EGFR mutation positive group, the disease control rate (DCR) was 95.8%, and the median progression-free survival (PFS) was 11 months. In EGFR mutation negative group, the DCR was 0%, and the median PFS was 1 month. The DCR and PFS were significantly different between the two groups (P<0.05).
CONCLUSIONS
According to the pathological quality control standards, the embedded section of pleural fluid sediment can be used to detect EGFR gene mutation, and the results can be used to guide the clinical use of EGFR-TKIs.
5.Clinical-radiological-pathological Characteristics of 297 Cases of Surgical Pathology Confirmed Benign Pulmonary Lesions in Which Malignancy Could Not Be Excluded in Preoperative Assessment: A Retrospective Cohort Analysis in a Single Chinese Hospital.
Yongjian LIU ; Minjiang CHEN ; Chao GUO ; Wei ZHONG ; Qiuyue YE ; Jing ZHAO ; Qing ZHOU ; Xiaoxing GAO ; Xiaoyan LIU ; Hongge LIANG ; Yuequan SHI ; Delina JIANG ; Hongsheng LIU ; Yan XU ; Shanqing LI ; Mengzhao WANG
Chinese Journal of Lung Cancer 2020;23(9):792-799
BACKGROUND:
Low dose computed tomography (LDCT) for lung cancer screening is widely employed in China as a result of increasing cancer screening awareness. Although some pulmonary lesions detected by LDCT are cancerous, most of the pulmonary nodules are benign. It is important to make effective preoperative differentiation of pulmonary lesions and to obviate the need for surgery in some patients with benign disease.
METHODS:
From January 1, 2017 to December 31, 2018, patients in our institution with surgical pathology confirmed benign pulmonary lesions in which malignancy could not be excluded in preoperative assessment were enrolled in this study. Retrospective analysis of clinical data was conducted.
RESULTS:
297 cases were collected in this study. Prevalence of benign disease in patients underwent resection for focal pulmonary lesions is 9.8% in our institution. In 197 patients (66.3%), pulmonary lesions were detected by LDCT screening. A total of 323 assessable pulmonary lesions were detected by chest CT. The average diameter of pulmonary lesions was (17.9±12.1) mm, and 91.0% of which were greater than or equal to 8 mm. Solid nodules accounted for 65.6% of these lesions. Imaging characteristics suggesting malignancy were common, including spicule sign (71/323, 22.0%), lobulation (94/323, 29.1%), pleural indentation (81/323, 25.1%), vascular convergence sign (130/323, 40.2%) and vacuole sign (23/323, 7.1%). 292 patients (98.3%) underwent video-assisted thoracoscopic surgery (VATS). Pulmonary wedge resection was performed in 232 cases (78.1%), segmental resection in 13 cases (4.4%) and lobotomy in 51 cases (17.2%). Surgical complications occurred in 4 patients (1.3%). The most frequent findings on surgical pathology analysis were: infectious lesions in 98 cases (33.0%), inflammatory nodules in 96 cases (32.3%), and hamartoma in 64 cases (21.5%).
CONCLUSIONS
Solid nodules accounted for most of these benign pulmonary lesions in which malignancy could not be excluded preoperatively, and imaging characteristics suggesting malignancy were common. VATS is an important biopsy method to identify etiology and pathology for lesions. The most frequent benign pulmonary diseases that are suspected to be malignant and underwent surgical resection are: infectious lesions, inflammatory nodules and hamartoma.
6.Advanced Pneumonic-type Lung Carcinoma: A Retrospective Study of Clinical-radiological-pathological Characteristics with Survival Analysis in A Single Chinese Hospital.
Yongjian LIU ; Ji LI ; Shibo WANG ; Minjiang CHEN ; Jing ZHAO ; Delina JIANG ; Wei ZHONG ; Yan XU ; Mengzhao WANG
Chinese Journal of Lung Cancer 2019;22(6):329-335
BACKGROUND:
Pneumonic-type lung carcinoma is a special type of lung cancer both clinically and radiologically. Here we present our experience on pneumonic-type lung carcinoma in an attempt to investigate the clinical, radiological and pathological features, diagnostic procedures, treatment, and prognosis of this type of tumor.
METHODS:
Pathologically confirmed lung cancer with a chest CT characterized by ground glass opacity or consolidation was defined as pneumonic-type lung carcinoma. Cases with advanced pneumonic-type lung carcinoma admitted to Peking Union Medical College Hospital (PUMCH) from January 1, 2013 to August 30, 2018 were enrolled. Retrospective analysis of clinical data and survival follow-up of these patients was conducted.
RESULTS:
A total of 46 cases were enrolled, all of which were adenocarcinoma. Cough (41/46, 89.1%) and expectoration (35/46, 76.1%) were the most prominent symptoms. The most frequent chest CT findings were ground glass attenuation (87.0%), patchy consolidation (84.8%), and multiple ground-glass nodules (84.8%). Multiple cystic changes (40%) and cavitation (13%) were also quite frequent. Ipsilateral and contralateral intrapulmonary metastasis were noted in 95.3% and 84.8% of cases respectively. The median duration from symptom onset to diagnosis was 214 days (95%CI: 129-298). Both surgical lung biopsy and CT-guided percutaneous lung biopsy had a diagnostic yield of 100%. Transbronchial lung biopsy (TBLB) combined with bronchoalveolar lavage (BAL) had a diagnostic yield of 80.9% (17/21). Sputum cytology had a diagnostic yield of 45% (9/20). Twenty-six cases were invasive mucinous adenocarcinoma (26/46, 56.5%) and the remainder were unable to identify pathological subtypes due to lack of adequate biopsy sample size. EGFR mutation was detected in 15.8% (6/38) of patients and ALK rearrangement was detected in 3.0% (1/33) of patients. The median overall survival for these patients was 522 d (95%CI: 424-619). In patients without EGFR mutation or ALK rearrangement, chemotherapy significantly improved survival (HR=0.155, P=0.002,2). The median overall survival was 547 d (95%CI: 492-602 d) with chemotherapy and 331 d (95%CI: 22-919) without chemotherapy.
CONCLUSIONS
Diagnosis of pneumonic-type carcinoma is usually delayed due to clinical and radiological features mimicking pulmonary infection. TBLB combined with BAL has a quite high diagnostic yield. The most frequent histological type is invasive mucinous adenocarcinoma. The incidence of EGFR mutation or ALK rearrangement is low in pneumonic-type carcinoma. For patients without cancer driver genes, chemotherapy is recommended to improve overall survival.
Aged
;
Anaplastic Lymphoma Kinase
;
genetics
;
metabolism
;
Antineoplastic Agents
;
therapeutic use
;
Carcinoma
;
diagnostic imaging
;
drug therapy
;
genetics
;
pathology
;
ErbB Receptors
;
genetics
;
metabolism
;
Female
;
Gene Rearrangement
;
Humans
;
Lung Neoplasms
;
diagnostic imaging
;
drug therapy
;
genetics
;
pathology
;
Male
;
Middle Aged
;
Mutation
;
Neoplasm Staging
;
Retrospective Studies
;
Survival Analysis
;
Tomography, X-Ray Computed
7.A Retrospective Study of 42 Lung Cancer Patients with Pancreatic Metastases.
Yu ZHANG ; Minjiang CHEN ; Jing ZHAO ; Wei ZHONG ; Yan XU ; Mengzhao WANG
Chinese Journal of Lung Cancer 2019;22(4):228-232
BACKGROUND:
A number of patients with lung cancer have distant metastases at the time of diagnosis. The most common sites for metastases are liver, brain, etc. However pancreatic metastasis is relatively rare, with an insidious onset and poor prognosis. There are no sufficient recognition and attention of lung cancer with pancreatic metastasis. The aim of this study was to summarize the pathological characteristics, clinical manifestations, therapies and prognosis of pancreatic metastases of lung cancer, thus further exploring better managements for the best prolonged survival or quality of life.
METHODS:
42 patients of lung carcinoma with confirmed pancreatic metastases hospitalized at the Peking Union Medical College Hospital from January 1998 to December 2018 were identified. We reviewed all medical documentations for complete information including diagnosis, treatment, prognosis features.
RESULTS:
24 (57%) patients were asymptomatic or presented with non-specific symptoms. 18 (43%) patients had symptoms related to pancreatic metastases, such as acute pancreatitis, obstructive jaundice or pain of lumber back. The median overall survival (OS) was 8.8 months. Multivariate analysis suggested patients with symptoms had a poor prognosis compared with patients without pancreatic symptoms [(hazard ratio, HR)=2.645, 95%CI: 1.013-6.910, P=0.047]. Patients received chemotherapy had better prognosis versus those who did not [HR=0.158, 95%CI: 0.049-0.512, P=0.002].
CONCLUSIONS
Pancreatic metastasis of lung cancer is rare and the prognosis is poor. Chemotherapy can prolong survival significantly. Local radiotherapy of the pancreas may alleviate local symptoms, improve quality of life, facilitate further systemic chemotherapy for patients to prolong survival. Patients with symptoms related to pancreatic metastases can benefit from the comprehensive treatment of chemotherapy combined with local pancreatic radiotherapy.
Aged
;
Female
;
Humans
;
Lung Neoplasms
;
pathology
;
Male
;
Middle Aged
;
Pancreatic Neoplasms
;
diagnosis
;
secondary
;
therapy
;
Prognosis
;
Quality of Life
;
Retrospective Studies
;
Survival Analysis
8.Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy in Advanced NSCLC Patients with EGFR Mutations.
Minjiang CHEN ; Yan XU ; Jing ZHAO ; Wei ZHONG ; Mengzhao WANG
Chinese Journal of Lung Cancer 2019;22(2):99-104
BACKGROUND:
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated some dramatic efficacy in advanced non-small-cell lung cancer (NSCLC) patients with activating EGFR mutation. However, progression-free survivals (PFS) among those patients who were treated with first line EGFR TKIs were inconsistent. The aim of this study is to explore the association of clinical prognostic factors with EGFR-TKI efficacy in advanced NSCLC patients.
METHODS:
The demographic and clinical characteristics of 203 patients with activating EGFR mutation treated with first generation TKI as a first-line therapy were retrospectively reviewed.
RESULTS:
Of the 203 patients enrolled in this study, 139 patients had progression of disease and 63 patients died. The subjects had a median follow up duration of 21.1months and a median PFS of 14.3 months. Partial response (PR) was achieved in 127 (66.1%) patients and stable disease (SD) rate was achieved in 55 (28.6%) patients. In univariate analysis, patients with 2 or higher ECOG score (5.1 vs 16 months, P=0.033), SD as best overall response (9.5 vs 17.9 months, P=0.030), extrathoracic metastasis (11.7 vs 27.5 months, P=0.004), liver metastasis (4.1 vs 16.0 months, P=0.000), bone metastasis (13.3 vs 21.5months, P=0.027) and pulmonary embolism (5.5 vs 16.6 months, P=0.005) had shorter PFS than those without the listed factors. Multivariable Cox regression analysis showed best overall response (HR=1.825, 95%CI: 1.107-3.008, P=0.018) and liver metastasis (HR=1.694, 95%CI: 1.146-5.756, P=0.022) were independent predictive factors of shorter PFS.
CONCLUSIONS
Despite the high efficacy of EGFR-TKI, SD as best overall response and liver metastasis predicts poorer PFS in advanced NSCLC patients with EGFR gene mutations receiving first-line therapy treatment.
Adult
;
Aged
;
Antineoplastic Agents
;
administration & dosage
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
enzymology
;
genetics
;
mortality
;
ErbB Receptors
;
genetics
;
metabolism
;
Female
;
Humans
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
Middle Aged
;
Mutation
;
Protein Kinase Inhibitors
;
administration & dosage
;
Retrospective Studies
;
Treatment Outcome
;
Young Adult
9.Endobronchial Ultrasound Guided Transbronchial Needle Aspiration for The Diagnosis and Genotyping of Lung Cancer.
Minjiang CHEN ; Chi SHAO ; Yan XU ; Xuefeng SUN ; Jing ZHAO ; Yong CHEN ; Yuanyuan ZHAO ; Wei ZHONG ; Mengzhao WANG
Chinese Journal of Lung Cancer 2018;21(9):670-676
BACKGROUND:
Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) has emerged as an innovative technique for diagnosis and staging of lung cancer. But whether the procedure can provide enough tissue for the detection of gene mutations is still to be defined. Here we evaluated the efficacy of lung cancer diagnosis and gene analysis using samples obtain via EBUS-TBNA.
METHODS:
Patients with suspected lung cancer and mediastinal lesions were referred for EBUS-TBNA. Diagnosis and sub-classifications were made by pathologists. Samples with non-squamous non small cell lung cancer sub type were tested for the EGFR and/or ALK mutations.
RESULTS:
A total of 377 patients were included in this study. The median needle passes were 2.07. Lung cancer was diagnosed in 213 patients. The diagnosis accuracy for malignancy was 92%. Epidermal growth factor receptor (EGFR) mutations, anaplasticlymphoma kinase (ALK) fusion genes and double genes analysis were successfully preformed in 84 (90%), 105 (95%) and 79 (90%) patients. The number of needle passes and the diameters of lymph node were not associated with the efficacy of gene testing in univariate analysis. However, samples of adenocarcinoma sub type showed a tendency associated with higher genotyping efficacy.
CONCLUSIONS
Tissue samples obtained through EBUS-TBNA are sufficient for pathological diagnosis and genetic analysis of lung cancer. The pathology type of sample affected genotyping efficacy.
Adult
;
Carcinoma, Non-Small-Cell Lung
;
diagnosis
;
genetics
;
pathology
;
Endoscopic Ultrasound-Guided Fine Needle Aspiration
;
Feasibility Studies
;
Female
;
Genotyping Techniques
;
Humans
;
Lung Neoplasms
;
diagnosis
;
genetics
;
pathology
;
Male
10.Indications for percutaneous renal biopsy in children with asymptomatic hematuria
Yufeng LI ; Minjiang WEI ; Weilan WU ; Huimin CHEN ; Yu DONG ; Jing JIN ; Yaju ZHU ; Yinliang GONG ; Wenjie SHAN
Journal of Clinical Pediatrics 2017;35(7):494-497
Objective To explore the indications for percutaneous renal biopsy of asymptomatic hematuria in children. Methods The renal pathological types of 485 children with asymptomatic hematuria were analyzed retrospectively. According to the degree of hematuria and whether or not combined with proteinuria, the children were divided into microscopic hematuria group, gross hematuria group and hematuria with proteinuria group. The microscopic hematuria group was further divided into urine red blood cell<15/HPF group, (15~30)/HPF group, and >30/HPF group according to hematuria degree. Results In 227 males and 258 females with the average age of 7.23±2.93 years, there were 318 cases in microscopic hematuria group, in which the most common pathological types were minor lesions (64.8%), followed by focal glomerular lesions (16.7%) and focal segmental glomerulosclerosis (8.2%). There were 119 cases in gross hematuria group, in which the most common pathological types were also minor lesions (26.1%), followed by IgA nephropathy (24.4%) and mesangial proliferative glomerulopathy (20.2%). There were 48 cases in hematuria with proteinuria group, in which the most common pathological types were IgA nephropathy (29.2%) and minor lesions (29.2%). The distribution of the pathological types among microscopic hematuria group, gross hematuria group and hematuria with proteinuria group were statistically different (χ2=152.03, P<0.001). In three groups, microscopic hematuria group had the highest proportion of minor lesions, while gross hematuria group and hematuria with proteinuria group had higher proportion of IgA nephropathy and mesangial proliferative glomerulonephritis . In microscopic hematuria group, there were 149 children with urine red blood cell<15/HPF, 96 with urine red blood cell (15~30)/HPF, and 73 with urine red blood cell >30/HPF. There was no difference in pathological types among three sub-groups (χ2=15.18, P=0.51), and mild lesions were the most common pathological types in each group. Conclusion Renal biopsy should be performed at earliest possible time to make pathological diagnosis in asymptomatic hematuria children with gross hematuria or proteinuria.

Result Analysis
Print
Save
E-mail